Prognostic Markers in the Era of Targeted Therapies

Area of Science:

• Hematology
• Oncology
• Pharmacology

Background:

• Targeted therapies, including Bruton's tyrosine kinase (BTK) inhibitors and B-cell lymphoma-2 (BCL-2) agents, have replaced chemoimmunotherapy (CIT) as standard care for chronic lymphocytic leukemia (CLL).
• The evolving treatment landscape necessitates reevaluation of prognostic markers for personalized medicine in CLL.
• Ongoing research focuses on targeted drug combinations and treatment cessation strategies based on minimal residual disease (MRD).

Purpose of the Study:

• To review prognostic markers in CLL patients undergoing targeted therapy.
• To assess the impact of genetic variables on treatment outcomes in CLL.
• To inform the development of risk-adapted treatment strategies for CLL.

Main Methods:

• Review of existing literature on prognostic markers in CLL.
• Analysis of clinical trial data for targeted therapies and chemoimmunotherapy (CIT).
• Examination of genetic markers such as TP53 aberration, IGHV mutation status, and complex karyotype.

Main Results:

• BTK inhibitors demonstrate superior progression-free survival (PFS) in TP53-aberrant CLL patients compared to CIT (70% vs. 15% at 5 years).
• Immunoglobulin heavy chain variable gene (IGHV) mutation status impacts PFS and overall survival differently across treatment modalities (CIT, venetoclax, BTK inhibitors).
• Unmutated IGHV is linked to poorer outcomes with FCR and fixed-duration venetoclax but not continuous BTK inhibitor therapy.

Conclusions:

• Genetic variables (TP53, IGHV, complex karyotype) hold significant prognostic value in CLL patients treated with targeted agents.
• Understanding these markers is essential for tailoring CLL treatment strategies.
• Prognostic marker evaluation is critical for optimizing risk-adapted therapy in the era of targeted CLL treatments.